Tyrosine kinase inhibitors (TKIs) are representative first-line anti-angiogenic targeted therapies to inhibit VEGF and its receptor (VEGFR) signaling in patients with metastatic ccRCC. Here, KDR is linked to nonpapillary renal cell carcinoma.